Investors Buy Eli Lilly And Co (LLY) on Weakness Following Insider Selling

Investors bought shares of Eli Lilly And Co (NYSE:LLY) on weakness during trading on Friday after an insider sold shares in the company. $128.72 million flowed into the stock on the tick-up and $71.40 million flowed out of the stock on the tick-down, for a money net flow of $57.32 million into the stock. Of all equities tracked, Eli Lilly And Co had the 33rd highest net in-flow for the day. Eli Lilly And Co traded down ($2.26) for the day and closed at $113.58Specifically, major shareholder Eli & Co Lilly sold 4,500 shares of Eli Lilly And Co stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $14.44, for a total transaction of $64,980.00. Following the completion of the sale, the insider now owns 3,915,654 shares of the company’s stock, valued at $56,542,043.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Alfonso G. Zulueta sold 6,000 shares of Eli Lilly And Co stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $106.31, for a total value of $637,860.00. Following the sale, the senior vice president now directly owns 55,224 shares of the company’s stock, valued at approximately $5,870,863.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,962,800 shares of company stock valued at $149,601,553. Corporate insiders own 0.11% of the company’s stock.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a research note on Wednesday. ValuEngine raised Eli Lilly And Co from a “hold” rating to a “buy” rating in a research note on Monday, October 8th. Barclays boosted their target price on Eli Lilly And Co from $112.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, October 12th. Citigroup lowered Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $115.00 target price for the company. in a research note on Monday, November 26th. Finally, Cantor Fitzgerald set a $110.00 target price on Eli Lilly And Co and gave the company a “buy” rating in a research note on Monday, September 17th. Nine analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Eli Lilly And Co currently has a consensus rating of “Buy” and an average price target of $111.53.

The stock has a market cap of $123.43 billion, a P/E ratio of 26.54, a P/E/G ratio of 1.82 and a beta of 0.31. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.53.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $1.35 by $0.04. The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. Eli Lilly And Co’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.05 EPS. Equities analysts predict that Eli Lilly And Co will post 5.58 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be given a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a yield of 1.98%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s payout ratio is 52.57%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in shares of Eli Lilly And Co during the 2nd quarter worth approximately $114,000. Fort L.P. purchased a new position in shares of Eli Lilly And Co during the 2nd quarter worth approximately $121,000. Welch Group LLC purchased a new position in shares of Eli Lilly And Co during the 3rd quarter worth approximately $123,000. Zions Bancorporation purchased a new position in shares of Eli Lilly And Co during the 3rd quarter worth approximately $128,000. Finally, Mainstay Capital Management LLC ADV grew its holdings in shares of Eli Lilly And Co by 98.0% during the 3rd quarter. Mainstay Capital Management LLC ADV now owns 1,218 shares of the company’s stock worth $131,000 after acquiring an additional 603 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/12/08/investors-buy-eli-lilly-and-co-lly-on-weakness-following-insider-selling.html.

About Eli Lilly And Co (NYSE:LLY)

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: What is Liquidity?

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply